Benchmark initiated coverage on BioTelemetry with a new price target
$BEAT
Medical/Dental Instruments
Health Care
Benchmark initiated coverage of BioTelemetry with a rating of Speculative Buy and set a new price target of $9.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/20/2026 | Buy → Hold | D. Boral Capital | |
| 3/31/2026 | $4.00 | Buy | B. Riley Securities |
| 3/27/2026 | $5.00 | Buy | D. Boral Capital |
| 3/16/2026 | $8.00 | Buy → Speculative Buy | The Benchmark Company |
| 12/11/2025 | $8.00 | Speculative Buy → Buy | The Benchmark Company |
| 12/8/2025 | $2.50 | Buy | H.C. Wainwright |
| 10/31/2025 | $4.00 | Buy | Roth Capital |
| 12/20/2021 | $9.00 | Speculative Buy | Benchmark |
D. Boral Capital downgraded HeartBeam from Buy to Hold
B. Riley Securities initiated coverage of HeartBeam with a rating of Buy and set a new price target of $4.00
D. Boral Capital initiated coverage of HeartBeam with a rating of Buy and set a new price target of $5.00
4/A - HeartBeam, Inc. (0001779372) (Issuer)
4 - HeartBeam, Inc. (0001779372) (Issuer)
4 - HeartBeam, Inc. (0001779372) (Issuer)
Publication in JACC: Advances demonstrates that an algorithm combining the HeartBeam ECG device with patient risk factors and symptoms can accurately identify heart attack risk Study advances the scientific foundation supporting HeartBeam's planned indication expansion into heart attack detection Large market potential with over 20 million patients in the U.S. at risk of a heart attack HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced a peer-reviewed article in JACC: Advances, a journal of the American College of Cardiology, demonstrating that a risk prediction algorithm incorpor
Signed First Commercial Partners in Leading Concierge Practices ClearCardio™ and Atelier Health Established Flagship Commercial Sites Across New York, Dallas, South Florida and Southern California Strategic Collaboration with Mount Sinai to Accelerate Next-Generation AI-ECG Algorithms, Starting with Heart Attack Detection Strengthened Balance Sheet with $11.5 Million Public Offering Including Full Exercise of Over-Allotment Option Initiated Heart Attack Detection Pilot Study, A Key Step Toward Future FDA Indication Expansion Initiated Pilot Study of First On-Demand 12-Lead ECG Patch to Detect Ischemia Outside the Clinic Management to Host Webcast and Conference Call Today
Ambulatory patch device designed to aid in detecting ischemia and complex arrythmias Targets a $2 billion market with established reimbursement; ischemia detection has potential to disrupt the patch market which is currently limited to atrial fibrillation detection HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, announced the initiation of a pilot study evaluating its novel on-demand 12-lead ECG patch in patients with suspected coronary artery disease. The study is being conducted at two leading hospitals in Belgrade, Serbia. The initiation of the pilot study represents a significant step in the
10-Q - HeartBeam, Inc. (0001779372) (Filer)
8-K - HeartBeam, Inc. (0001779372) (Filer)
424B5 - HeartBeam, Inc. (0001779372) (Filer)
4/A - HeartBeam, Inc. (0001779372) (Issuer)
4 - HeartBeam, Inc. (0001779372) (Issuer)
4 - HeartBeam, Inc. (0001779372) (Issuer)
SC 13D - HeartBeam, Inc. (0001779372) (Subject)
SC 13D - HeartBeam, Inc. (0001779372) (Subject)
SC 13D - HeartBeam, Inc. (0001779372) (Subject)
HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, will hold a conference call on Wednesday, May 13, 2026 at 4:30 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2026, and will be providing updates on key strategic growth initiatives, including its limited commercial launch for arrhythmia assessment, and developments on its extended-wear patch, heart attack detection and AI initiatives. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answe
HeartBeam Enters New Growth Phase Following FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment First Commercial Partner ClearCardio™ to Bring HeartBeam's 3D ECG Technology to High-Growth Preventive Cardiology Market First Patients Enrolled in Heart Attack Detection Pilot Study, A Key Step Toward Future FDA Indication Expansion Completed the First Working Prototype of an Extended-Wear 12-Lead ECG Patch Strategic Collaboration with the Icahn School of Medicine at Mount Sinai to Accelerate Next-Generation AI-ECG Algorithms Management to Host Webcast and Conference Call Today at 4:30 p.m. ET HeartBeam, Inc. (NASDAQ:BEAT), a
HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, will hold a conference call on Thursday, March 12, 2026 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2025, and will be providing updates on its key strategic growth initiatives, specifically the limited commercial launch and significant developments on the 12-lead ECG extended wear patch. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. They will
Brings more than 25 years of experience in building and scaling groundbreaking cardiovascular technologies Will initially focus on launching the Company's FDA-cleared 12-lead ECG system for arrhythmia assessment Will lead the Company's broader commercialization strategy across key growth initiatives, including heart attack detection and the 12-lead ECG extended-wear patch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the appointment of Bryan Humbarger as Chief Commercial Officer, effective January 22, 2026. In this newly created role, Mr. Humbarger will lead commercial strate
Board expansion reflects Company's commitment to leadership and innovation in remote cardiac monitoring HeartBeam, Inc., (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced the appointment of Chief Executive Officer, Robert Eno, to its Board of Directors. As the Company continues to make significant advancements towards commercial readiness, the Board elected to expand from eight to nine members to accommodate this addition. Mr. Eno joined HeartBeam as President in January 2023 and was appointed CEO in October 2024. With over 30 years of experience in the medical technology industry, he has a proven
First cable-free, ambulatory ECG that captures the heart's electrical signals from three distinct directions for high-fidelity data collection and advanced diagnostics Patients can have the credit card-sized device with them at all times, ready to record an ECG whenever they feel symptoms and reduce delays in care Company to initiate Early Access Program to gain important patient and physician feedback on the use of the system in preparation for commercial launch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the US Food and Drug Administration (FDA) has granted 510(k) cl